Prostatype Genomics AB
Prostatype Genomics AB is a Swedish publicly listed medtech company (sto:PROGEN) that develops and sells the Prostatype prognostic gene test for prostate cancer, serving urologists and oncologists in the Nordics while pursuing US market entry.
- Company typePrivate
- Founded2007
- HeadquartersSolna, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Prostatype Genomics AB does
Prostatype Genomics AB is a Swedish medical technology company founded in 2007 and headquartered in Solna, Sweden, that manufactures, markets, and sells Prostatype, a proprietary prognostic gene test for prostate cancer. The company is publicly listed on the Stockholm Stock Exchange under the ticker sto:PROGEN and operates with a small team of 1-10 employees, targeting healthcare providers — specifically urologists and oncologists — as its primary customer segment.
The core product, Prostatype, is positioned as a prognostic gene test, implying analysis of gene-expression signatures to forecast prostate cancer outcomes and inform treatment decisions; however, the source material does not disclose the underlying algorithm, biomarker panel, or laboratory workflow. No patents, certifications, or product-level technical details are enumerated in the available data, and the technology block characterizes the firm only as a "medical technology company focused on prostate cancer diagnostic solutions."
Commercially, the company has yet to disclose a pricing model, revenue, or named customers. It has funded operations through equity issuances — a warrant exercise in April 2024 raising approximately SEK 7.3 million (~81% subscription) and a planned SEK 47 million preferential rights issue in July 2026 conditional on a Medicare-related regulatory milestone — with capital earmarked for US market entry. The company serves the Nordic region from its home market and is actively pursuing entry into the United States, supported by a dedicated US-based President and a Chief Medical Officer.
Prostatype Genomics AB firmographics
Firmographics- Name
- Prostatype Genomics AB
- Legal name
- Prostatype Genomics AB
- Website
- https://prostatypegenomics.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Prostatype Genomics AB is a Swedish publicly listed medtech company (sto:PROGEN) that develops and sells the Prostatype prognostic gene test for prostate cancer, serving urologists and oncologists in the Nordics while pursuing US market entry.
- Ownership category
- akta.pro rank
Prostatype Genomics AB industry classification
Industry- Product category
- Prostate Cancer Diagnostics
- NAICS
- Medical Laboratories (621511)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industry
- Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Prostatype Genomics AB is headquartered
LocationHeadquarters
- HQ city
- Solna
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Prostatype Genomics AB business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Marketing or Sales, Operations, Personnel
Prostatype Genomics AB product offering
Product offeringCore offering
Prostatype Genomics AB is a Swedish medical technology company that manufactures, markets, and sells Prostatype, a prognostic gene test used by urologists and oncologists to support prostate cancer diagnosis and treatment decisions. The company is actively strengthening its market entry into the United States following recent capital raises through warrant exercises and rights issues.
Differentiator
Problem solved
Functional benefit
Products and services
- Prostatype
Companies that use Prostatype Genomics AB
Customer profileSegments1 record
Ideal customer profiles1 record
Prostatype Genomics AB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Prostatype Genomics AB partnerships and signals
Strategic signalScale indicators4 records
Recent moves4 records
Expansion highlights4 records
Prostatype Genomics AB competitors and assessment
Company assessmentDirect peers
- MDxHealth: MDxHealth markets SelectMDx and ConfirmMDx, two of the most direct commercially available prostate cancer genomic tests. It is the closest head-to-head competitor to Prostatype, competing for the same urologist customer and similar payor coverage pathways.
- Veracyte (Decipher Biosciences): Veracyte's Decipher Prostate genomic classifier is a prognostic test used by urologists to guide treatment decisions after prostate cancer diagnosis. It is one of the most clinically validated competitors in the same prognostic niche Prostatype targets.
- Myriad Genetics: Myriad has a long-standing genetic-testing franchise including Prolaris (prostate cancer prognostic test). It competes with Prostatype in the same prognostic space with deeper payor coverage and an established US sales force.
- Exact Sciences (Genomic Health): Exact Sciences, through its acquisition of Genomic Health, markets Oncotype DX Genomic Prostate Score, a directly comparable prognostic gene-expression test for prostate cancer. It is one of the most well-capitalized and commercially entrenched peers in this category.
- OPKO Health (4Kscore): OPKO Health's 4Kscore test is a blood-based prostate cancer diagnostic used by urologists to aid biopsy decisions. It is a directly comparable commercial prostate cancer diagnostic, even though it is positioned earlier in the diagnostic pathway than Prostatype.
- Guardant Health: Guardant Health is a leader in oncology genomics with liquid biopsy and tissue-based genomic profiling products. It overlaps with Prostatype in the broader oncology genomic-testing category and represents a potential competitor or strategic acquirer as it expands into prognostic and treatment-decision applications.
- NanoString Technologies: NanoString developed the Decipher GRID and PAM50-based gene-expression assays used in oncology, including prostate cancer prognostic applications. It is comparable as a technology platform for gene-expression-based prognostic tests aimed at urologic oncology.
Broad incumbents
- NeoGenomics: NeoGenomics is a large US-based oncology-focused clinical laboratory offering a broad menu of molecular and genetic tests, including for prostate cancer. It is a much larger, broader incumbent in the oncology testing space and is comparable as a go-to-market reference for US oncology diagnostics.
- Foundation Medicine (Roche): Foundation Medicine, owned by Roche, provides comprehensive genomic profiling of tumors. While not focused on prostate prognostic testing specifically, it is a broad incumbent in oncology genomics and sets the bar for clinical evidence and payor coverage in the category.
Emerging players
- Strand Life Sciences: Strand Life Sciences is an emerging genomics and clinical diagnostics company with a growing oncology and hereditary cancer testing portfolio. It is comparable as a smaller, multi-product genomics company navigating similar clinical-evidence and payor-coverage challenges in oncology diagnostics.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Prostatype Genomics AB social profiles
Digital presenceProstatype Genomics AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prostatype Genomics AB leadership team
Management profileNumber of profiles
Profiles3 records
Prostatype Genomics AB funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prostatype Genomics AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prostatype Genomics AB
What does Prostatype Genomics AB do?
Prostatype Genomics AB is a Swedish medical technology company that manufactures, markets, and sells Prostatype, a prognostic gene test used by urologists and oncologists to support prostate cancer diagnosis and treatment decisions. The company is actively strengthening its market entry into the United States following recent capital raises through warrant exercises and rights issues.
Is Prostatype Genomics AB a public or private company?
Prostatype Genomics AB is a private company. It is classified as public and is currently operating.
When was Prostatype Genomics AB founded?
Prostatype Genomics AB was founded in 2007. It employs 1 to 10 people.
Where is Prostatype Genomics AB based?
Prostatype Genomics AB is headquartered in Solna, Sweden, in the Europe region.
Who are Prostatype Genomics AB's main competitors?
Direct peers on record are MDxHealth, Veracyte (Decipher Biosciences), Myriad Genetics, Exact Sciences (Genomic Health), OPKO Health (4Kscore), Guardant Health and NanoString Technologies. Broad incumbents are NeoGenomics and Foundation Medicine (Roche). Strand Life Sciences is listed as an emerging player.
Does Prostatype Genomics AB have an API?
No public API is recorded for Prostatype Genomics AB.
What industry is Prostatype Genomics AB in?
Prostatype Genomics AB's product category is Prostate Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 621511.